Product Information
COPAXONE 40 MG/ML SYRINGE is a brand product labeled by Teva Neuroscience, Inc., priced at $541.1156 per ML under NDC 68546032512. Its NADAC has been published 637 times since Jul 23, 2014.
FDA first approved this application on Dec 20, 1996. Its Orange Book therapeutic-equivalence code is AP.
The High Outlier badge above means this manufacturer's average price in the Glatiramer Acetate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/mL
Manufacturer
Teva Neuroscience, Inc.NDC
68546032512
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
GLATIRAMER ACETATEApproval Type
New Drug (NDA)
FDA Application
NDA020622FDA Approved
12/20/1996
TE Code
AP
On Market Since
1/29/2014
Price Statistics
The NADAC for COPAXONE 40 MG/ML SYRINGE has been published 637 times since Jul 23, 2014, and over the history we have for it it has risen 45.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $541.1156 per ML |
|---|---|
| All-time high | $541.7390 (May 13, 2026) |
| All-time low | $371.9568 (Jul 23, 2014) |
| 52-week high | $541.7390 |
| 52-week low | $495.1664 |
| Median price | $471.3698 |
| Average price | $464.3994 |
| Largest weekly change | +9.4% (Jan 7, 2026) |
| Weeks tracked | 637 |
| Tracking since | Jul 23, 2014 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 84% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Neuroscience, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glatiramer Acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COPAXONE 40 MG/ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for COPAXONE 40 MG/ML SYRINGE, manufactured by Teva Neuroscience, Inc., is $541.1156 per ML (NDC 68546032512), effective Sep 30, 2026.
How has the price of COPAXONE 40 MG/ML SYRINGE changed over time?
Over the history we have for it, the NADAC for COPAXONE 40 MG/ML SYRINGE has risen 45.5%. It has been tracked across 637 weekly CMS publications since Jul 23, 2014.
What are the highest and lowest recorded NADAC prices for COPAXONE 40 MG/ML SYRINGE?
Since Jul 23, 2014, the NADAC for COPAXONE 40 MG/ML SYRINGE has ranged from a low of $371.9568 (Jul 23, 2014) to a high of $541.7390 (May 13, 2026), with a median of $471.3698 per ML.
Are there cheaper alternatives to COPAXONE 40 MG/ML SYRINGE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GLATOPA 40 MG/ML SYRINGE, is $86.0952 per ML — about 84% below COPAXONE 40 MG/ML SYRINGE.
Who manufactures COPAXONE 40 MG/ML SYRINGE?
COPAXONE 40 MG/ML SYRINGE (NDC 68546032512) is labeled by Teva Neuroscience, Inc., and CMS classifies it as a brand product.